Mayzent® (siponimod) – New drug approval
March 26, 2019 - The FDA announced the approval of Novartis’ Mayzent (siponimod), for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Top